Eli Lilly launches Lormalzi in India, a once-monthly Alzheimer's therapy for mild impairment. It targets amyloid plaques to ...
Zacks Investment Research on MSN
Lilly bets on next-generation obesity drugs to stay ahead
Eli Lilly and Company LLY is a leader in the fast-growing diabetes and obesity market, driven by its blockbuster ...
Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...
Eli Lilly is set to launch Lormalzi, a groundbreaking monthly injection targeting amyloid plaques for Alzheimer's treatment, ...
The prescription-only drug, Lormalzi can help the body remove the excessive buildup of amyloid plaques and slow the decline ...
Eli Lilly introduces Lormalzi in India, a new Alzheimer's therapy targeting amyloid plaques. Priced at Rs 91,688 per month.
MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained ...
1d
Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study finds
Eli Lilly said on Tuesday that patients in a late-stage trial who had been taking an injectable GLP-1 medication for over a ...
India’s regulators are tightening oversight as obesity drug makers race to shape demand in the country’s emerging weight-loss ...
Eli Lilly paused its obesity awareness campaign in India after the nation's drugs regulator warned the company it could ...
Zacks Investment Research on MSN
NVO rallies 21% in a month: How should investors play the stock?
Shares of Novo Nordisk NVO have surged 21.3% over the past month, driven by stronger-than-expected first-quarter 2026 results ...
While Pfizer is playing catch-up in the GLP-1 race, it has several irons in the fire that could turn its business around.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results